Showing results (101-110 of 1,343) with videos related to

Sort By:
Pageof 135
The Pharmacogenomics Journal|February 15, 2019
Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patientsLuz M Canet, Jose M Sánchez-Maldonado, Rafael Cáliz, et al.
The Pharmacogenomics Journal|February 24, 2018
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancerK Tryfonidis, C Papadaki, S Assele, et al.
The Pharmacogenomics Journal|February 24, 2016
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapyQ Feng, W Q Wei, C P Chung, et al.
The Pharmacogenomics Journal|August 28, 2002
Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disordersM K Hahn, R D Blakely
The Pharmacogenomics Journal|August 28, 2002
Efficient discovery of single-nucleotide polymorphisms in coding regions of human genesG Hu, B Modrek, H M F Riise Stensland, et al.
The Pharmacogenomics Journal|November 20, 2002
Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) studyD K Arnett, E Boerwinkle, B R Davis, et al.
The Pharmacogenomics Journal|August 22, 2003
Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cellsM Brun, S Bourdoulous, P O Couraud, et al.
The Pharmacogenomics Journal|August 22, 2003
Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosisH Ujike, M Harano, T Inada, et al.
The Pharmacogenomics Journal|June 26, 2002
Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment responseD Di Bella, S Erzegovesi, M C Cavallini, et al.
The Pharmacogenomics Journal|October 5, 2016
A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trialsA Sebio, S Stintzing, V Heinemann, et al.
Pageof 135